What The FDA's Latest Move On Psychedelics Means For Non-Hallucinogenic Drug Sponsors

A conversation between Enveric Biosciences CEO Joseph Tucker, Ph.D., and Clinical Leader Executive Editor Abby Proch

The Psychedelic Drugs resource page added to the FDA website might be yet another indicator that the regulator is increasingly interested in the field’s potential. In publishing this resource page, which sits alongside one dedicated to drug repurposing, the agency has coalesced July’s finalized guidance for the field and April’s executive order as well as information on its September 2025 Part 15 Hearing, Priority Voucher program, and collaboration with the Department of Veterans Affairs. 

The steady progress and openness in this regard is not lost on Joseph Tucker, Ph.D., CEO of Enveric Biosciences, which is advancing a non-hallucinogenic neuroplastogen to treat mental health conditions.  

A different take than that offered by Psychedelic Alpha’s Josh Hardman, Tucker discusses what that evolving FDA posture means for sponsors, how non-hallucinogenic neuroplastogens may fit into the broader landscape, and why companies developing these therapies still must meet the same standards for safety, efficacy, and interpretable evidence as any other drug developer.

The April 2026 executive order on psychedelic drug development signaled federal interest in accelerating neuropsychiatric innovation. How does the FDA’s resource page represent a next step, or a more concrete regulatory signal, in that broader story?

The executive order indicated that the administration wants to make psychedelic drug development a priority, and the FDA resource page is showing how the agency is actually putting the policy into practice. The page’s contents of relevant guidance, priority review initiatives, and interagency work show sponsors that the FDA is treating this as an established drug development category rather than a series of unusual one-off programs.

This enables companies to now see more clearly which issues the FDA considers important, including blinding, psychological support, acute behavioral effects, abuse potential, and monitoring.

For Enveric, that clarity is helpful since our lead molecule, EB003, comes from the same broader scientific arena but is specifically designed not to produce the acute psychedelic experience that creates many of the regulatory complications that the FDA is discussing. This clearer framework helps us show where EB003 fits within the field and, perhaps more importantly, where it differs.

Even with the executive order and the resource page, what remains unchanged?

The executive order and the resource page are good steps in the right direction, while, importantly, the approval standard has not changed. Every drug still must demonstrate safety and efficacy in well-controlled clinical trials. Sponsor companies still need a complete nonclinical package, reliable manufacturing, appropriate clinical pharmacology, a justified dose, and a safety database that supports the intended use. Even as the executive order may help improve coordination or speed up certain reviews, it does not replace the need for adequate evidence. A company cannot use enthusiasm around psychedelics as a substitute for good data.

For EB003, our job is still to show in Phase 1 that the molecule has an acceptable safety, tolerability, and pharmacokinetic profile, and then show in Phase 2 that it produces a meaningful clinical benefit. The potential advantage for Enveric is that EB003 may meet that bar without many of the added complications caused by an acute psychedelic state.

Enveric is developing non-hallucinogenic neuroplastogenic therapies. How does that approach fit into the psychedelic-derived medicine landscape, and where does it differ from traditional psychedelic-assisted treatment models?

We are part of the same scientific movement, but we are pursuing a different treatment model. The work of many in the psychedelic field has helped validate the idea that serotonergic biology and neuroplasticity may produce meaningful benefits in difficult-to-treat neuropsychiatric conditions. Enveric is trying to retain that useful biology while separating it from hallucinations and the prolonged altered state.

With EB003, our goal is a conventional oral medicine that could be used in an outpatient setting, not one that requires a patient to spend most of the day in a clinic, undergo an intense subjective experience, or receive the drug alongside specially structured psychotherapy. We believe that distinction matters scientifically, clinically, and commercially.

In psychedelic-assisted therapy, it can be difficult to separate the effect of the drug from the effect of the patient’s expectations, the therapist, and the treatment setting. With EB003, we should be able to evaluate the molecule more like a conventional pharmaceutical. If the clinical data support that, it could also make the treatment much easier to prescribe and scale.

Do you expect non-hallucinogenic approaches to face a different regulatory path than therapies with an acute psychedelic experience?

The formal path is the same, as both types of drugs proceed through an IND, clinical trials, and, ultimately, an NDA. In practice, though, the path could be quite different.

Many of the FDA’s concerns about psychedelics come from the acute experience itself. Those concerns include functional unblinding, impaired judgment, patient vulnerability, abuse-related effects, prolonged monitoring, transportation after treatment, and the role of psychological support. We believe a genuinely non-hallucinogenic drug may be able to avoid much of that.

However, in the psychedelic drug class, sponsors must prove the lack of hallucinogenicity before being able to benefit from a simpler pathway. For EB003, that means measuring perceptual effects, cognition, dissociation, euphoria, judgment, and other subjective effects carefully in Phase 1. If we demonstrate lack of hallucinogenicity in humans clearly, the development and regulatory path for EB003 should look much more like a conventional CNS drug program.

What kinds of companies or therapeutic approaches are best positioned to benefit from a more defined FDA framework around psychedelic or psychedelic-derived medicines?

The companies that benefit most will be the ones that are already doing serious drug development, with a strong nonclinical package, interpretable clinical trials, and a realistic plan for how the treatment would be delivered. Essentially, the more defined framework helps companies that have already designed their programs around the questions FDA actually needs to have answered.

For a traditional psychedelic, that means taking head-on the issues around unblinding, acute behavioral effects, psychotherapy, patient monitoring, and the treatment infrastructure. For a non-hallucinogenic program, it’s about showing that the drug retains therapeutic activity without triggering those same issues. This is where EB003 may be especially well positioned, because we designed and developed it to avoid those limitations.

Conversely, why might some companies in the space benefit less than others from these regulatory developments?

Regulatory clarity can expose weaknesses as well as strengths. It is possible that some companies may have built programs around small studies, unusual treatment settings, intensive therapist involvement, or patient populations that already strongly expect to receive a psychedelic. Those studies may produce strong efficacy signals, but it can be difficult to know how much of the result came from the drug itself, yet that is exactly what the FDA needs to know to approve a drug for sale.

The FDA does not only ask whether a patient has improved. The clinical trial data needs to clearly and convincingly reveal why the patient improved, whether the result is reliable, and whether the treatment can be delivered safely in real clinical practice. A company with a drug that requires substantial monitoring, trained therapists, and a full day in a treatment center may still develop a valuable medicine, but the challenge is greater for it to get the drug approved.

To what extent should the executive order and the FDA’s psychedelic drug resource page impact sponsors’ approach to clinical trial design for non-hallucinogenic neuroplastogens?

The issues that the FDA identifies for psychedelics should absolutely influence clinical trial design for non-hallucinogenic neuroplastogens.

For non-hallucinogenic neuroplastogens, Phase 1 needs to do more than establish routine safety, tolerability, and pharmacokinetics. It should also directly measure whether the drug causes perceptual changes, dissociation, euphoria, impaired cognition, or other effects that could either compromise blinding or require monitoring. For this, sponsors will need to use validated subjective-effect scales, investigator observations, and assessments of whether subjects or investigators could guess the treatment assignment.

Later, in Phase 2 studies, the design should confirm that clinical benefit can be demonstrated without needing psychotherapy or an elaborate treatment setting, preferably in an outpatient setting. Achieving that would help establish that the effect comes from the drug rather than the environment surrounding administration and also open the door to outpatient treatment for the drug once it is ultimately approved.

Finally, looking ahead, what specific actions from the FDA or other federal agencies would most help translate today’s policy and regulatory signals into real clinical progress?

The most useful next step would be clearer FDA guidance on how the framework applies to non-hallucinogenic compounds that engage some of the same biological targets as psychedelics. A drug should be regulated based on what it actually does in patients, not simply because its chemistry or receptor pharmacology is related to a classic psychedelic. The regulatory distinctions between psychedelics and non-hallucinogenic neuroplastogens is still a bit fuzzy.

It would also help to have more specific FDA feedback on acceptable control groups, how to measure functional unblinding, what evidence is needed to show that prolonged monitoring is unnecessary, and how sponsors should evaluate durability and repeat dosing. These are all still works in progress.

For companies developing traditional psychedelics, that means knowing exactly how to address the acute experience. For Enveric, it means having a clear route to show that EB003 can deliver neuroplastic and therapeutic benefits without running into the same regulatory and practical burdens.

About The Expert:

Joseph Tucker, Ph.D., is a seasoned executive who has built several publicly traded biotechnology companies. Tucker was a founder and CEO of Stem Cell Therapeutics, which he took public on the TSX; Trillium Therapeutics acquired Stem Cell Therapeutics in 2013. Tucker has also held the position of cofounder and CEO of Epimeron Inc., a University of Calgary startup acquired in the creation of Willow Biosciences Inc. At Willow, Tucker served as executive chairman and COO. Prior to founding companies, Tucker was a healthcare analyst with two investment banks and has also worked in technology commercialization for a university technology transfer office. Tucker received his Ph.D. in biochemistry and molecular biology from the University of Calgary.